Recent Quotes (30 days)

You have no recent quotes
chg | %

Neovasc Inc  

(Public, CVE:NVC)   Watch this stock  
Find more results for neovasc
-0.35 (-5.19%)
Apr 24 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 6.40 - 6.42
52 week 2.17 - 7.85
Open 6.42
Vol / Avg. 895.00/10,911.00
Mkt cap 336.51M
P/E     -
Div/yield     -
EPS -0.02
Shares 52.58M
Beta 0.88
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -39.62% -4.49%
Operating margin -39.13% -63.03%
EBITD margin - -61.29%
Return on average assets -60.37% -4.65%
Return on average equity -74.06% -5.48%
CDP Score - -


Suite 2135, 13700 Mayfield Place
+1-604-2704344 (Phone)
+1-604-2704384 (Fax)

Website links


Neovasc Inc. (Neovasc) is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. Its products include the Neovasc Reducer for the treatment of refractory angina, the Tiara technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as vascular surgical patches and transcatheter heart valves. Neovasc manufactures the PeriPatch line of advanced biological tissue products that are manufactured from pericardium, which is the protective sac that surrounds the heart of an animal. The product line includes the PeriPatch Sheet, and PeriPatch EQ Sheet, which are rectangular patches made from bovine (cow) or equine (horse) tissue, applied as internal bandages to repair weak or damaged organs or vessels.

Officers and directors

Paul L Geyer Chairman of the Board
Age: 46
Alexei J Marko Chief Executive Officer, Director
Age: 43
Chris Clark Chief Financial Officer
Brian McPherson Chief Operating Officer
Jane H. Hsiao Ph.D. Independent Director
Age: 66
Douglas G. Janzen Independent Director
Age: 41
William O'Neill Independent Director
Age: 61
Steven D. Rubin Esq. Independent Director
Age: 52